DMD, an acronym for Duchenne muscular dystrophy, refers to a genetic disorder that primarily affects boys and leads to the progressive weakening and degeneration of their muscles. This neuromuscular condition is caused by a mutation in the gene that is responsible for producing dystrophin, a protein crucial for maintaining the structure and health of muscle fibers. DMD is typically diagnosed during childhood, around the ages of three to six.
The symptoms of DMD usually become noticeable within the first few years of a child's life, with affected individuals experiencing difficulties in walking, running, and other physical activities. As the disorder progresses, muscle weakness and deterioration become more severe, leading to mobility challenges and potentially affecting the respiratory and cardiac systems. DMD is commonly associated with muscle wasting, delayed motor development, and decreased muscle tone.
There is currently no cure for DMD, and treatment primarily focuses on managing the symptoms to improve the quality of life for individuals with the condition. Approaches can include physical therapy, assistive devices such as braces or wheelchairs, and medications to address specific symptoms and complications.
Given the severity and lifelong impact of Duchenne muscular dystrophy, research and medical advancements continue in hopes of finding more effective treatments and potential cures for this debilitating condition.
